The CD4 cell count at which to initiate HIV-associated cryptococcal antigen (CrAg) screening and pre-emptive antifungal treatment among CrAg positive persons may need to be raised to 200 cells/μL. Evidence based on a meta-analysis

doi:10.21203/rs.2.14337/v2

Download PDF

Review

The CD4 cell count at which to initiate HIV-associated cryptococcal antigen (CrAg) screening and pre-emptive antifungal treatment among CrAg positive persons may need to be raised to 200 cells/μL. Evidence based on a meta-analysis

https://doi.org/10.21203/rs.2.14337/v2

This work is licensed under a CC BY 4.0 License

Journal Publication

published 12 Jun, 2020

Read the published version in BMC Infectious Diseases →

You are reading this older preprint version

Read the latest preprint version →

Background: Current WHO guidelines (2018) recommend screening for cryptococcal antigen (CrAg) in HIV-infected persons with CD4<100 cells/μL, followed by pre-emptive antifungal therapy among CrAg positive (CrAg+) persons, to prevent Cryptococcal meningitis related deaths. The strategy may also be considered for those persons with a CD4 count of<200 cells/uL according the WHO guidelines. However, there remains little evidence for doing so in those HIV-infected persons with this CD4 cell count.

Objective: We aimed to assess the necessity of CrAg screening and the efficacy of pre-emptive antifungal therapy in CrAg+ persons with CD4<200 cells/µL.

Methods: We conducted a meta-analysis using data obtained from randomized controlled studies (RCTs) and cohort studies found in Pubmed, Web of Science, Cochrane Library and EMBASE/MEDLINE.

Results: The pooled prevalence of CrAg positivity in HIV-infected persons with CD4<200 cells/µL was 5% (95%CI: 3-6). The incidence of CM in CrAg+ persons was 7- fold (7%, 95%CI: 4-10) that of CrAg negative (CrAg-) persons (1%, 95%CI: 0-1). Among CrAg+ persons who did not receive any treatment or only received placebo, the incidence of CM was 9% (95%CI: 5-13), whereas the incidence of CM among those who received antifungal therapy was 2% (95%CI: 0-3), a highly statistically significant reduction of 78% (RR: 6.03, 95%CI: 2.74-13.24, p<0.00001).

Conclusions: In our meta-analysis, the incidence of CM in CrAg+ persons were significantly higher than in CrAg- persons with CD4<200 cells/µL. Furthermore, the incidence of CM was significantly reduced by pre-emptive antifungal therapy in CrAg+ persons with CD4<200 cells/µL.

Infectious Diseases

HIV

cryptococcal antigenemia

CD4

pre-emptive treatment

meta

Cryptococcal meningitis (CM) continues to cause significant mortality in HIV-infected individuals (1, 2) resulting in 181100 deaths globally each year (3). In resource-limited regions such as sub-Saharan Africa, 75% of HIV-related deaths are due to CM (3). However, cryptococcal antigen (CrAg) can be detected in blood several weeks to months (22 days on average) before the onset of signs and symptoms of meningitis (4, 5) and therefore, can be used as a trigger for pre-emptive antifungal therapy in HIV-infected individuals with low CD4 cell counts. According to previous studies, pre-emptive antifungal therapy in CrAg+ persons is imperative to preventing death (6-8). Firstly, the prevalence of CrAg positivity among HIV-infected individuals can be considerable, ranging between 1% to 16% in several African and Southeast Asian countries (9), and among persons with CD4<100 cells/µL, the prevalence of CrAg positivity averages 7% with regional variation (3). Secondly, CrAg positivity resulted in a 20% increase in mortality at the time of antiretroviral therapy (ART) initiation (10), and the risk of CM in CrAg+ persons was as high as 25% during the first year of ART if fluconazole pre-emptive therapy was not prescribed (11, 12).

According to the 2018 version of the WHO guidelines, routine CrAg screening and pre-emptive antifungal therapy are recommended in treatment-naive HIV persons with CD4<100 cells/µL (13). The guidelines also state that these strategies may also be considered for HIV-infected persons with CD4<200 cells/µL (13), suggesting that the evidence for the necessity of CrAg screening and the efficacy of implementing pre-emptive antifungal therapy in HIV persons with a higher CD4 cell count level is not sufficient enough to include them deterministically in these recommendations. Therefore, we conducted a meta-analysis to investigate whether routine CrAg screening and pre-emptive antifungal treatment in HIV-infected persons with <200 cells/µL would be beneficial.

Search strategy and article screening

We searched relevant English articles in Pubmed, Cochrane Library, MEDLINE/EMBASE and Web of Science from inception until the end of September 15^th 2018. The search terms we used were as follows: ‘acquired immunodeficiency syndrome’, “HIV”, “AIDS”, “cryptococcosis”, and “prophylaxis”. We combined these terms by using “and” or “or”. To avoid missing significant articles, we also screened references of previous meta-analyses and their included studies for eligibility.

Two reviewers (Yao Li, Yuanyuan Qin) independently screened all obtained articles by titles and abstracts. After removing ineligible articles by inclusion and exclusion criteria, the remaining articles were further selected by full-text reviewing.

Inclusion and exclusion criteria

Inclusion criteria

Randomized-controlled studies (RCTs) or cohort studies were included with the following criteria:

Study subjects had baseline CD4 cell counts<200 cells/μL.
CrAg was tested for study subjects.
Fluconazole or other azole medications were used as the intervention.

Exclusion criteria

We excluded articles if: (1) all of the study subjects were diagnosed with CM or asymptomatic CM; (2) sample size was less than 50; or (3) the incidence of CM and all-cause mortality was unreported.

Data extraction and quality assessment

The data we extracted included first author, publication year, type of study, study duration, location, total number of persons, number of CrAg+ or CrAg- persons, baseline CD4 cell counts, age, CrAg screening methods, diagnostic methods of CM, CM events, death events, adverse effects, other opportunistic infections. The JBI (Joanna Briggs Institue) Critical Appraisal Checklist for Cohort Studies was used as a quality assessment tool for cohort studies (14). The potential bias risk of the RCT was assessed using the Cochrane “risk of bias” tool (15).

Data analysis

The proportion of CrAg positivity, the incidence of CM, and all-cause mortality were performed by STATA 14 (Statacorp, Texas, USA) with a 95% confidence interval (95%CI). We used random-effects or fixed-effects models in Review manager 5.3 (The Nordic Cochrane Center, Copenhagen) to compare the incidence of CM and all-cause mortality in CrAg+ persons.

We evaluated statistical heterogeneity through visual inspection of forest plots. Statistical heterogeneity was also assessed by I² statistics (16), which was considered non-negligible if I²>50%. Herein, random-model was applied if I²>50% and fixed-model was used when I²<50% (17). Reporting bias was assessed by examining asymmetry of funnel plots (16).

The protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO), and the registration number is CRD42018110980.

In total, 490 articles were obtained from 4 databases, among which 276 were from Pubmed, 106 were from Web of Science, 12 were from Cochrane Library, and 96 were from MEDLINE/EMBASE. 82 of the 490 articles were RCTs or cohort studies. Additional 12 articles (RCTs or cohort studies) were extracted from references of previous meta-analyses and their included studies.

All the 94 RCTs or cohort studies were included for screening. Firstly, 9 articles (6 from Web of Science and 3 from MEDLINE/EMBASE) were reduplicative and were therefore excluded from the 94 articles. Next, after screening titles and abstracts, 43 of the remaining 85 articles were excluded. Then, 25 articles were excluded from the remaining 42 articles after screening full-text, among which 1 article was news report, 3 articles reported patients with cryptococcal disease, 2 articles reported HIV-negative patients with cryptococcal antigenemia, 4 articles reported patients with CM or asymptomatic CM, 6 articles reported HIV-infected patients with negative CrAg, 1 article reported the epidemiology of cryptococcosis and 8 articles did not report CD4 cell counts or primary outcomes. Finally, 17 articles were included in our meta-analysis.

The characteristics of the included 17 studies were shown in Table 1. The assessment of quality and potential risk bias showed that the following may contribute to clinical and methodological heterogeneity, including: (1) the confounding factors or subject recruiting or incomplete follow-up in 7 of the 16 cohort studies, (2) the unclear risk of attrition in the RCT, and (3) the unclear risk of reporting and other bias in the RCT, as shown in Supplementary Table 1 and Supplementary Table 2.

Twelve of the 17 included studies reported the prevalence of CrAg positivity (1735 persons with CD<200 cells/μL in 3 studies; 783 persons with CD<150 cells/μL in 1 study; 3876 persons with CD<100 cells/μL in 8 studies). The pooled CrAg positivity prevalence in 6394 HIV infected persons with CD<200 cells/μL was 5% (95%CI: 3-6, I²=85.5%) (Figure 2).

Thirteen studies reported the incidence of CM among CrAg+ persons (1789 persons with CD<200 cells/μL in 3 studies; 312 persons with CD<150 cells/μL in 2 study; 248 persons with CD<100 cells/μL in 8 studies), and 4 studies reported the incidence of CM among CrAg- persons (54 persons with CD<200 cells/μL in 1 studies; 2107 persons with CD<100 cells/μL in 3 studies). The incidence of CM in 2349 CrAg+ persons was 7% (95%CI: 4-10; P=0.000; I²=74.6%), whereas the incidence of CM in 2161 CrAg- persons was 1% (95%CI: 0-1; P=0.343; I²=10.0%). The former is 7 times that of the latter (Figure 3 A and Table 2).

Nine studies reported the incidence of CM among persons who received antifungal therapy (909 persons with CD<200 cells/μL in 3 studies; 166 persons with CD<200 cells/μL in 2 studies; 88 persons with CD<100 cells/μL in 2 studies), and 9 studies reported the incidence of CM among persons who received placebo or no intervention (946 persons with CD<200 cells/μL in 3 studies; 146 persons with CD<150 cells/μL in 1 study; 160 persons with CD<100 cells/μL in 5 studies). The incidence of CM of 1163 persons receiving antifungal therapy was 2% (95%CI: 0-3; P=0.008; I²=61.1%), whereas the incidence of CM of 1252 persons in 9 studies who received placebo or no intervention was 9%, a 78% reduction (95%CI: 5-13; P=0.000; I²=73.7%) (Figure 3 B and Table 2).

Four studies compared the incidence of CM between 1081 persons receiving azoles and 1072 persons receiving placebo or no intervention (1768 persons with CD<200 cells/μL in 2 studies; 295 persons with CD<150 cells/μL in 1 study; 90 persons with CD<100 cells/μL in 1 study). We found that the risk ratio of CM events among persons who received placebo or no intervention was 6.03 times of those who received antifungal therapy (95%CI: 2.74-13.24; P<0.00001; I²=17%).

Thirteen of the 17 included studies reported all-cause mortality among CrAg+ persons (1936 persons with CD<200 cells/μL in 5 studies; 312 persons with CD<150 cells/μL in 2 studies; 255 persons with CD<100 cells/μL in 6 studies), 6 studies reported all-cause mortality in CrAg- persons (54 persons with CD<200 cells/μL in 1 study; 2087 persons with CD<100 cells/μL in 5 studies). The all-cause mortality of 2503 CrAg+ persons was 18% (95%CI: 11-25; P=0.000; I²=94.0%), 1.06 times that of 2141 CrAg- persons (17%, 95%CI: 3-31; P=0.000; I²=99.0%), which is shown in Figure 4A and Table 2.

Nine studies reported all-cause mortality in persons who received antifungal therapy (230 persons with CD<200 cells/μL in 4 studies; 166 persons with CD<150 cells/μ in 2 studies L; 88 persons with CD<100 cells/μL in 3 studies), 7 studies reported all-cause mortality in persons receiving placebo or no intervention (946 persons with CD<200 cells/μL in 3 studies; 146 persons with CD<150 cells/μL in 1 study; 110 persons with CD<100 cells/μL in 3 studies). The all-cause mortality of 484 persons receiving antifungal therapy was 16% (95%CI: 10-22; P=0.002; I²=67.3%), which was same to that of 1202 CrAg- persons receiving placebo or no intervention (16%, 95%CI: 7-24; P=0.000; I²=92.4%) (Figure 4A and Table 2).

Five studies (1897 persons with CD<200 cells/μL in 3 studies; 295 persons with CD<150 cells/μL in 1 study; 90 persons with CD<100 cells/μL in 1 study) compared all-cause mortality between persons who received azole antifungal therapy and persons who received placebo or no intervention. No significant difference was found in all-cause mortality (risk ratio: 0.82, 95%CI: 0.42-1.600; P=0.55; I²=61%) between 1144 CrAg+ persons who received an azole drug and 1138 CrAg+ persons who received placebo or no intervention (Figure 5).

In addition, we estimated and compared the prevalence of CrAg positivity, the incidence of CM and all-cause mortality between persons with CD4<100 and persons with CD4 100-200 cells/μL. The results showed that the risk ratio of CrAg positivity prevalence among HIV-infected persons with CD4<100 cells/μL was 2.69 times that of those with 100-200 cells/μL (95%CI: 1.48-4.88; p=0.001, I²=34%; 2 studies; 1672 persons) (Table 3). The risk ratio of the incidence of CM among HIV-infected persons with CD4<100 cells/μL was 4.96 times that of those with CD4 100-200 cells/μL (95%CI: 1.94-12.68, p=0.23, I²=31%; 3 studies, 1943 persons). The risk ratio of the all-cause mortality among HIV-infected persons with CD4<100 cells/μL was 4.15 times that of those with CD4 100-200 cells/μL (95%CI: 0.89-19.42, p=0.07, I²=0%; 2 studies, 1552 persons) (Table 3). Further, the risk ratio of the incidence of CM among persons with CD4 100-200 cells/μL receiving antifungal treatment was 0.90 compared to those receiving placebo or no intervention (95%CI: 0.06-13.89, p and I² not applicable; 2 studies; 135 persons) (Table 3). The risk ratio of the all-cause mortality among persons with CD4 100-200 cells/μL receiving antifungal treatment was 0.27 compared to those receiving placebo or no intervention (95%CI: 0.01-4.93, p and I² not applicable; 1 study; 7 persons) (Table 3).

Several meta-analyses have been conducted to evaluate the necessity of CrAg screening and pre-emptive antifungal treatment among HIV-infected CrAg+ persons with varying CD4 levels. For example, Temfack et al investigated the effectiveness of CrAg detection and the initiation of pre-emptive fluconazole treatment in HIV-infected persons with cryptococcal antigenemia and CD4<100 cells/µL (16). Their results suggested that offering fluconazole pre-emptive therapy to CrAg+ persons greatly reduced the risk of incident CM and may have survival benefits (16). Another meta-analysis conducted by Ssekitoleko et al also suggested that CrAg+ persons, in resource-limited settings, should routinely receive primary antifungal prophylaxis (18), but they did not clarify at which CD4 cell count levels antifungal prophylaxis should be initiated. Ford et al’s (19) meta-analysis only reported the combined prevalence of cryptococcal antigenemia among HIV-infected persons with CD4≤100 and with CD4 101~200 cells/µL. Importantly, their study did not mention whether pre-emptive antifungal treatment was necessary or effective among HIV-infected persons with cryptococcal antigenemia at these two CD4 strata. From the above studies, the necessity and benefits of CrAg screening and pre-emptive antifungal therapy remain unknown at higher CD4 counts. The purpose of our meta-analysis was to investigate the necessity and benefits of CrAg screening and azole pre-emptive antifungal therapy among HIV-infected persons with cryptococcal antigenemia and CD4<200 cells/µL.

The pooled prevalence of CrAg positivity in HIV-infected persons was 5% (12 studies) in our meta-analysis, 6% (31 studies with) in Temfack’s meta-analysis (16) and 6.5% (60 studies) in Ford’s meta-analysis (19). The incidence of CM in CrAg+ persons was 7 times that of in CrAg- persons with CD4<200 cells/µL and all-cause mortality in CrAg+ persons was 1.06 times that of CrAg- persons. The incidence of CM in Temfack’s study was 21.4% among CrAg+ persons and 0.4% in CrAg - persons (16). All-cause mortality in Temfack’s study among CrAg+ persons was significantly higher than in CrAg-persons: 39.7% vs 13.9%, respectively (16). From the above results, it is clear that regardless of whether the CD4 count is less than 200 or 100 cells/µL, the incidence of CM is higher in CrAg+ persons than in CrAg- persons. Therefore, antifungal prophylaxis seems necessary for HIV-infected persons with cryptococcal antigenemia and CD4<200 cells/µL.

Our results showed that the risk ratio of CM events among persons who received placebo or no intervention was significant higher than those who received antifungal therapy, suggesting that antifungal prophylaxis still significantly reduced the risk of CM events in CrAg + persons with a higher CD4 cell count level. However, the limited number of studies and included participants contributed to the insignificance of risk ratio in the CM incidence between persons with CD4 100-200 cells/μL receiving antifungal treatment and those receiving placebo or no intervention. More trials are still needed to verify the benefits of antifungal treatment in HIV-infected persons with CD4 100-200 cells/μL.

As for all-cause mortality, no significant difference was found in our meta-analysis among CrAg+ persons when receiving pre-emptive antifungal therapy versus receiving placebo or no intervention. The reason of this may be associated with the discrepant sample sizes in the two groups (493 vs. 1259). In addition, no difference was found among persons with CD4 100-200 cells/μL receiving antifungal therapy versus receiving placebo or no intervention, which could be explained by the same reason (4 vs. 3).

We considered the following possible reasons for clinical and methodological heterogeneity: follow-up time of reporting CM events and death events, dosing or course or type of antifungal therapy, ART status of subjects, and risk of bias. For example, the study durations ranged from 1 year to 6 years, and the dosing of azole antifungal treatments ranged from 100 mg to 800 mg. As for reporting bias, the unformed funnel plot for all-cause mortality may be associated with the different ART status of study participants, different dosage and duration of treatment and the different follow-up time in each of the studies.

There are some limitations in our study. Firstly, the data supporting the association between prevalence of CrAg positivity and adverse outcomes in HIV-infected persons with CD4 100-200 cells cells/μL was quite limited. Secondly, there has been a lack of fresh data of CrAg positivity prevalence, CM incidence and all-cause mortality in HIV-infected persons with CD4<200 cells/μL since 2015 (33), and our pooled outcome analyses heavily relied on older studies which may be less applicable to the modern test-and-treat era. And thirdly, the dosage and durations of azole therapy was not assessed in our meta-analysis. All of the above limitations may contribute to the clinical and methodological heterogeneity in our study.

In conclusion, our meta-analysis found that in HIV-infected persons with CD4<200 cells/μL, the incidence of CM was higher in those CrAg+ than in those CrAg-, and that azole pre-emptive treatment significantly reduced the incidence of CM in CrAg+ persons with CD4<200 cells/μL. Our results support that the CD4 cell count at which to initiate HIV-associated CrAg screening and pre-emptive antifungal treatment among CrAg+ persons may need to be raised to 200 cells/μL.

- Ethics approval and consent to participate

Not applicable.

- Consent to publish

Not applicable.

- Availability of data and materials

All the data and materials were available from Pubmed, Cochrane Library, MEDLINE/EMBASE and Web of Science.

- Competing interests

All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

- Funding

This work was supported by the national science and technology major project of China during the 13th Five-year plan period (2018ZX10302104, 2017ZX10201101), Major Project of Beijing Municipal Science and Technology Committee (D161100000416003, D171100000517003), the National Natural Science Foundation of China (No. 81701984), Beijing Key Laboratory (No. BZ0089), and 2018 Beijing You'an Hospital Scientific Research Project for Young & Middle-aged Talent’s Cultivation (NO. YNKTTS20180107).

- Authors' Contributions

YL, XJH, HW, XFY and YKC conceived and designed the protocol and study. YL, YYQ, JHH and AXL identified studies to be screened. XJH and HC identified studies for eligibility, extracted data and assessed the methodology quality of included studies. YL performed the analysis with assistance from XJH, and YKC. All authors read and approved the final manuscript.

- Acknowledgements

Thanks to all authors for their contributions to this manuscript.

Author details

1. Division ofInfectious Diseases, Chongqing Public Health Medical Center, Chongqing, China,

2. Center for Infectious Diseases, Beijing You’an Hospital, Capital Medical University, Beijing, China,

3. School of Biomedical Engineering, Capital Medical University, Beijing, China.

Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM and Karstaedt AS. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. HIV Med, 2015;16(8):468-76.
Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, et al. Cryptococcal Antigen Screening in persons Initiating ART in South Africa: A Prospective Cohort Study. Clin Infect Dis, 2016;62(5):581-587.
Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis, 2017;17(8):873-881.
French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 2002;16(7): 1031-8.
Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N, et al. Screening HIV-Infected persons with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. PLoS One, 2016;11(7):e0158986.
AwotiwonAA,Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people. Cochrane Database Syst Rev. 2018;2018(8): CD004773.
Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67.
Sathyanarayanan V, Razak A, Chakraborty J. Clinical profile of disseminated cryptococcal infection – a case series. Asian Pacific Trop Med. 2010;3:818–20
Kaplan JE, Vallabhaneni S, Smith RM, Chideya-chihota S, Chehab J and Park B. Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature. JAIDS, 2015;68(Suppl 3):331-339.
Beyene T, Woldeamanuel Y, Asrat D, Ayana G, Boulware DR. Comparison of Cryptococcal Antigenemia between Antiretroviral Naïve and Antiretroviral Experienced HIV Positive persons at Two Hospitals in Ethiopia. PLoS One, 2013;8(10):e75585.
Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R and Harrison TS. Screening for cryptococcal antigenemia in persons accessing an antiretroviral treatment program in South Africa. Clin Infect Dis, 2009);48(7):856-62.
Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing Cryptococcosis Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. Curr Trop Med Rep, 2015;2(2): 81-9.
World Health Organization. Guidelines for the diagnosis, prevention and management of Cryptococcal disease in HIV-infected adults, adolescents and children march 2018;http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/
The Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2016 edition. Australia: The Joanna Briggs Institute; 2016.
Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.
Temfack E, Bigna JJ, Luma HN, Spijker R, Meintjes G, Jarvis JN, et al. Impact of routine cryptococcal antigen screening and targeted pre-emptive fluconazole therapy in antiretroviral naive HIV-infected adults with less than 100 CD4 cells/μL: a systematic review and meta-analysis. Clin Infect Dis, 2018;doi: 10.1093/cid/ciy567
Huang Y, Huang X, Luo Y, Zhou Y, Tao X, Chen H, et al. Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected persons: A Meta-Analysis of Key Evidence to Support WHO Recommendations. Front Pharmacol, 2018;9:890.
18. Ssekitoleko R, Kamya MR, Reingold AL. Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. Future Virol, 2013;8(9).
19. Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clin Infect Dis, 2018;66(suppl_2):S152-S159.
20. Chariyalertsak S, Supparatpinyo K, Sirisanthana T and Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in persons with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis,2002;34(2):277-84.
21. Manfredi R, Mastroianni A, Coronado OV and Chiodo F. Fluconazole as prophylaxis against fungal infection in persons with advanced HIV infection. Arch Intern Med, 1997;157(1):64-9. PMID: 8996042
Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, et al. Primary prophylaxis of cryptococcal disease with ﬂuconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis, 2011;11:933–41.
McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in persons with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis, 1999;28(5):1049-56.
Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P and Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected persons with severe immune deficiency. HIV Med, 2004;5(3):140-3.
Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis, 2010;51: 448-55.
Kapoor SW, Magambo KA, Kalluvya SE, Fitzgerald DW, Peck RN, Downs JA. Six-month outcomes of HIV-infected persons given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. AIDS, 2015; 29(18):2473-8.
Vallabhaneni S, Longley N, Smith M, Smith R, Osler M, Kelly N, et al. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa. J Acquir Immune Defic Syndr, 2016;72(2):e37-e42.
Rick F, Niyibizi AA, Shroufi A, Onami K, Steele SJ, Kuleile M, et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho. PLoS One, 2017;12(9):e0183656.
Kwan CK, Leelawiwat W, Intalapaporn P, Anekthananon T, Raengsakulrach B, Peters PJ, et al. Utility of Cryptococcal Antigen Screening and Evolution of Asymptomatic Cryptococcal Antigenemia among HIV-Infected Women Starting Antiretroviral Therapy in Thailand. J Int Assoc Provid AIDS Care, 2014;13(5):434-7.
Ganiem AR, Indrati AR, Wisaksana R, Meijerink H, van der Ven A, Alisjahbana B, et al. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive persons in Indonesia. J Int AIDS Soc, 2014;17:18821.
Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health, 2007;12(8):929-35.
Linares L, Paz J and Bustamante B. Cryptococcalantigenemia in HIV infected persons with a CD4 count ≤ 100 cell mm^-3. Mycoses Vol, 2012;55: 206-207.
Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015;http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en

Table 1. Characteristics of the 17 included studies.

Author, year (reference)

Number of participants

Study type

Study duration

Age (years)

CD4 (cells/µL)

CrAg screening methods

CM diagnostic methods

Location

Therapeutic regimens

Other OIs or adverse effects

Primary outcomes

Incidence of CM

All-cause mortality

Chariyalertsak, 2002 (20)

129

Prospective study

104 weeks

18~60

＜200

Not report

Fungal culture, a histopathological examination, or buffy coat smear

Thailand

63 for oral itraconazole (200 mg/day) as group 1; 66 for matched placebo as group 2

Yes

0 in group 1; 7 in group 2

12 in group 1; 11 in group 2

Manfredi, 1997 (21)

249

Retrospective study

6 years

22~59

＜200

Not report

Specific polysaccharide

antigen detection from body fluids

Italy

128 for oral fluconazole (100 mg/d every third week) as group 1; 121 for no antifungal treatment as group 2

Yes

2 in group 1 ; 9 in group 2

12 in group 1; 13 in group 2

Parkes-Ratanshi, 2011 (22)

1519

Prospective study

42 months

Not report

＜200

Not report

CrAg titre>1:8 on two occasions, or a positive CSF CrAg or Cryptococcus neoformans grown from blood or CSF culture

Uganda

760 fluconazole 200 mg 3 times per week for minimum 12 weeks as group 1; 759 allocated to placebo as group 2

Yes

1 in group 1; 18 in group 2

0 in group 1; 7 in group 2

McKinsey, 1999 (23)

295

Randomized, placebo-Controlled study

Not report

≥13

＜150

Not report

Fungal culture

Not report

149 for itraconazole capsules (200 mg/day) as group 1; 146 for matched placebo as 2

Yes

1 in group 1; 8 in group 2

32 in group 1; 21 in group 2

Chetchotisakd, 2004 (24)

Prospective study

18 months

>14

＜100

Not report

Thailand

3 received fluconazole (400 mg weekly) as group 1; 7 received placebo as group 2

Not report

3 in group 1; 7 in group 2

2 in group 1; 9 in group 2

Meya, 2010 (25)

584

Prospective study

30 months

≥18

＜200

Not report

Uganda

Fluconazole (200~400 mg) for 2~4 weeks

Not report

3 in CrAg+ persons and 0 in CrAg- persons

6 in CrAg+ persons and 0 in CrAg- persons

Kapoor, 2015 (26)

Retrospective study

15 months

≥18

＜200

LFA

Positive CSF India ink

sub-Saharan Africa

800 mg fluconazole orally for 2 weeks, followed by 400 mg orally for 2 weeks

Not report

0 in CrAg+ persons and 1 in CrAg- persons

2 in CrAg+ persons and 8 in CrAg- persons

Govender, 2015* (1)

1079

Retrospective study

19 months

Not report

< 200

LA or the Latex-Cryptococcus antigen detection system

CrAg detected in CSF

South Africa

Fluconazole ranging from 400 to 800 mg per day for at least 3 months

Not report

unknow in persons with CD4<200

Beyene, 2017 (10)

783

Prospective study

18 months

>14

≤150

LFA

CSF CrAg

Ethiopia

Fluconazole 800 mg/day 2 weeks, followed by 400 mg/day 8 weeks

Not report

2 in CrAg+ persons and 0 in CrAg- persons

4 in CrAg+ persons and 0 in CrAg- persons

Vallabhaneni, 2016 (27)

1159

Retrospective study

1 year

≥18

＜100

Laboratory-confirmed

South Africa

Fluconazole (any dose and any duration)

Not report

0 in CrAg+ persons and 9 in CrAg- persons

Rick, 2017 (28)

128

Observational study

1 year

Not report

＜100

LFA

Lumbar puncture and CSF testing using the CrAg LFA

Lesotho

Fluconazole for 10 weeks

Not report

2 in CrAg+ persons and No in CrAg- persons

3 in CrAg+ persons and No in CrAg- persons

Kwan, 2014 (29)

Observational study

48 weeks

31 (median)

<100

India ink stain of CSF

Thailand

Fluconazole 400 mg taken orally weekly

Not report

2 in CrAg+ persons and 0 in CrAg- persons

0 in CrAg+ persons and 4 in CrAg- persons

Longley, 2016 (2)

638

Prospective study

3 years

>18

≤100

LFA and LA

CSF CrAg-LFA

South Africa

Fluconazole 800 mg/day for 2 weeks, 400 mg/day for 8 weeks, and 200 mg daily thereafter

Not report

4 in CrAg+ persons and 2 in CrAg- persons

7 in CrAg+ persons and 71 in CrAg- persons

Ganiem, 2014 (30)

810

Prospective study

4 years

Not report

＜100

Semiquantitative LFA

Cryptococcus found in CSF, either with direct India ink staining or positive CrAg in CSF

Indonesia

Fluconazole administrated part persons: 18 in 30 CrAg+ persons and 102 in 294 CrAg- persons

Not report

6 in CrAg+ persons and 0 in CrAg- persons

18 in CrAg+ persons and 385 in CrAg- persons

Jarvis, 2009 (11)

315

Retrospective study

1 year

34 (mean)

19~77

Microbiologically confirmed

South Africa

No intervention

Not report

6 in CrAg+ persons and 0 in CrAg- persons

9 in CrAg+ persons and 38 in CrAg- persons

Liechty, 2007 (31)

377

Retrospective study

18 months

≥ 18

≤100

Not report

Uganda

No intervention

Not report

3 in CrAg+ persons and 4 in CrAg- persons

5 in CrAg+ persons and 19 in CrAg- persons

Linares, 2012 (32)

365

Retrospective study

12 months

Not report

≤100

LFA

Not report

Peruvian, Latin-America

No intervention

Not report

3 in CrAg+ persons and 0 in CrAg- persons

0 in CrAg+ persons and 0 in CrAg- persons

“No” means “no data”; “Yes” means “data exist”; OIs means: other opportunity infections.

*: “Govender, 2015” study was included for evaluating the prevalence of CrAg positivity. Only the data in persons with CD4<200 was used. “LFA”: lateral flow assay; “LA”: Latex Agglutination; LP lumbar puncture

Table 2. The incidence of CM and all-cause mortality among CrAg+ and CrAg- persons, and among persons with and without antifungal therapy.

Incidence of CM among CrAg+ and CrAg- persons	Number of reported studies	Number of persons	ES (95%CI)	I²	p
1.1 Incidence of CM among CrAg+ persons	13	2349	0.07 (0.04, 0.10)	74.6%	0.000
1.2 Incidence of CM among CrAg- persons	4	2161	0.01 (0.00, 0.01)	10.0%	0.343
Incidence of CM among persons with and without antifungal therapy	Number of reported studies	Number of persons	ES (95%CI)	I²	p
2.1 Incidence of CM among persons with antifungal therapy	9	1163	0.02(-0.00, 0.03)	61.1%	0.0008
2.2 Incidence of CM among persons without antifungal therapy	9	1252	0.09 (0.05, 0.13)	73.7%	0.000
All-cause mortality in CrAg+ and CrAg-persons	Number of reported studies	Number of persons	ES (95%CI)	I²	p
1.1 All-cause mortality among CrAg+ persons	13	2503	0.18 (0.11, 0.25)	94.0%	0.000
1.2 All-cause mortality among CrAg- persons	6	2141	0.17 (0.03, 0.31)	99.0%	0.000
All-cause mortality among persons who with and without antifungal therapy	Number of reported studies	Number of persons	ES (95%CI)	I²	p
2.1 All-cause mortality among persons with antifungal therapy	9	484	0.16 (0.10, 0.22)	67.3%	0.002
2.2 All-cause mortality among persons without antifungal therapy	7	1202	0.16 (0.07, 0.24)	92.4%	0.000

Table 3. Comparions of CrAg positivity, incidence of CM and all-cause mortality among HIV-infected persons stratified by CD4

Author, year	Prevalence of CrAg positivity		Incidence of CM				All-cause mortality
	CD4＜100 (cells/µL)	CD4 100~200 (cells/µL)	CD4＜100 (cells/µL)		CD4 100~200 (cells/µL)		CD4＜100 (cells/µL)		CD4 100~200 (cells/µL)
			with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment
Chariyalertsak, 2002 (18)	Not reported		0 of 40	6 of 45	0 of 23	0 of 21	Not reported		Not reported
Parkes-Ratanshi, 2011 (20)	Not reported		17 of 698		2 of 821		3* of 698		0* of 821
McKinsey, 1999 (21)	Not reported		0 of 101	7 of 103	1 of 48	1 of 43	Not reported		Not reported
Meya, 2010 (23)	26 of 295	7 of 298	3 of 21	2 of 5	Not reported		6 of 21	5 of 5	0 of 4	1 of 3
Govender, 2015 (1)	20 of 708	6 of 371	Not reported		Not reported		Not reported		Not reported
	The pooled CrAg+ prevalence: 0.06 [-0.00, 0.11], p=0.001, I²=91.3%	The pooled CrAg+ prevalence: 0.02 [0.01, 0.03], p=0.504, I²=0%	Risk ratio with 95%CI: 0.13 [0.03, 0.49], p=0.36, I²=1%		Risk ratio with 95%CI: 0.90 [0.06, 13.89], p and I² not applicable		Risk ratio with 95%CI: 0.32 [0.16, 0.64], p and I² not applicable		Risk ratio with 95%CI: 0.27 [0.01, 4.93] , p and I² not applicable
Risk ratio with 95%CI	2.69 [1.48, 4.88], p=0.001, I²=34%		4.96 [1.94, 12.68], p=0.23, I²=31%				4.15 [0.89, 19.42], p=0.07, I²=0%

*: Died within four weeks

3Revisedsupplementarymaterials.doc

Download PDF

Journal Publication

published 12 Jun, 2020

Read the published version in BMC Infectious Diseases →

Editorial decision: Major revision
17 Mar, 2020
Review #1 received at journal
07 Mar, 2020
Review #2 received at journal
07 Mar, 2020
Editor assigned by journal
26 Feb, 2020
Reviewers invited by journal
26 Feb, 2020
Reviewer #1 agreed at journal
26 Feb, 2020
Reviewer #2 agreed at journal
26 Feb, 2020
Submission checks completed at journal
25 Feb, 2020
Editor invited by journal
25 Feb, 2020

You are reading this older preprint version

Read the latest preprint version →

The CD4 cell count at which to initiate HIV-associated cryptococcal antigen (CrAg) screening and pre-emptive antifungal treatment among CrAg positive persons may need to be raised to 200 cells/μL. Evidence based on a meta-analysis

Status:

Journal Publication

Version 2

Abstract

Figures

Introduction

Method

Results

Discussion

Declarations

Reference

Tables

Supplementary Files

Status:

Journal Publication

Version 2